StockNews.com cut shares of Dynavax Technologies (NASDAQ:DVAX - Free Report) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.
Several other equities research analysts also recently commented on DVAX. HC Wainwright upped their target price on Dynavax Technologies from $29.00 to $31.00 and gave the company a "buy" rating in a report on Tuesday, January 14th. The Goldman Sachs Group downgraded Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their target price for the company from $15.00 to $12.00 in a report on Tuesday, February 11th.
View Our Latest Stock Analysis on Dynavax Technologies
Dynavax Technologies Price Performance
DVAX stock traded up $0.13 during trading hours on Wednesday, hitting $12.82. 924,380 shares of the stock traded hands, compared to its average volume of 1,540,363. The stock has a 50-day simple moving average of $12.80 and a 200 day simple moving average of $11.94. Dynavax Technologies has a one year low of $9.74 and a one year high of $13.89. The company has a market cap of $1.69 billion, a P/E ratio of 98.62 and a beta of 1.32. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.
Institutional Investors Weigh In On Dynavax Technologies
Hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 1,685 shares in the last quarter. US Bancorp DE lifted its stake in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,034 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 2,034 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in Dynavax Technologies in the 3rd quarter worth about $45,000. 96.96% of the stock is owned by hedge funds and other institutional investors.
Dynavax Technologies Company Profile
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
